STOCK TITAN

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial
Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq: EIGR) will host a conference call on December 8, 2022, at 8:30 AM ET to discuss the Phase 3 D-LIVR study results of their lonafarnib-based treatments for hepatitis delta virus (HDV). This study is significant as Eiger focuses on developing innovative therapies for HDV and other rare diseases. The company’s HDV platform features two first-in-class therapies currently in Phase 3 trials, both of which have received FDA Breakthrough Therapy designation. Investors can access the live call and its replay via Eiger's website.

Positive
  • Eiger's HDV platform includes two first-in-class therapies in Phase 3 trials.
  • Both therapies have received FDA Breakthrough Therapy designation.
  • Significant focus on developing innovative treatments for HDV.
Negative
  • None.

Live Conference Call and Webcast at 8:30 AM ET

PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, dial (866) 374-5140 (U.S.) or (404) 400-0571 (International) and enter PIN 79797687#. The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com    

Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-to-discuss-phase-3-d-livr-study-results-of-lonafarnib-based-treatments-in-hepatitis-delta-virus-hdv-on-thursday-december-8-2022-301697555.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What is the purpose of the Phase 3 D-LIVR study by Eiger?

The Phase 3 D-LIVR study aims to evaluate the efficacy of lonafarnib-based treatments for hepatitis delta virus.

When will Eiger discuss the Phase 3 study results?

Eiger will discuss the Phase 3 study results on December 8, 2022, at 8:30 AM ET.

How can I access the Eiger conference call?

The Eiger conference call can be accessed live by phone or via a webcast on their website.

What is lonafarnib being tested for?

Lonafarnib is being tested as a treatment for hepatitis delta virus in Eiger's clinical trials.

Has Eiger received any regulatory designations for their therapies?

Yes, both therapies in Eiger's HDV platform have received FDA Breakthrough Therapy designation.

Eiger BioPharmaceuticals, Inc.

NASDAQ:EIGR

EIGR Rankings

EIGR Latest News

EIGR Stock Data

2.55M
1.27M
11.8%
43.86%
2.27%
Biotechnology
Healthcare
Link
United States
Palo Alto